Products and Services
We offer a specialized suite of products and testing services focused on polyethylene glycol (PEG) allergy and anaphylaxis. Our core offering is the PEG-specific IgE detection kit, developed for use with flow cytometry—a highly sensitive method that allows precise identification of PEG-specific immunoglobulin E (IgE) antibodies in human blood samples. In addition to the primary detection kit, we provide essential auxiliary reagents including PEG IgE standards and validated positive and negative controls, ensuring accuracy and reproducibility across laboratory applications. These products are intended for use by trained professionals in equipped laboratory settings with flow cytometry instrumentation.
For organizations or clinicians lacking access to flow cytometers, we provide sample testing as a service, offering a streamlined solution for PEG allergy screening without the need for in-house technical infrastructure. Clients can submit serum samples to our lab for analysis, and we return results with interpretation guidance. Whether through direct product usage or outsourced testing, our platform enables reliable detection of PEG-specific IgE, aiding in the diagnosis and management of PEG-induced allergic reactions, including life-threatening anaphylaxis.
Who Are Interested and Can Be Served
PEG Allergy Researchers and Scientists
Researchers investigating the immunogenicity of PEG benefit from access to validated, flow cytometry–based tools that quantify PEG-specific IgE antibodies. These assays are critical for understanding the prevalence, mechanisms, and risk factors of PEG hypersensitivity in both clinical and research contexts. Our standardized kits and controls enable reproducible measurements and support publication-quality results, aiding academic, translational, and pharmaceutical research.
Individuals with Known PEG Allergy or Unexplained Anaphylaxis
For individuals who have experienced allergic reactions after exposure to PEG-containing products—or who have a history of unexplained anaphylaxis—our testing services provide much-needed clarity. Detecting anti-PEG IgE antibodies in these patients enables clinicians to identify PEG as the likely trigger and to recommend lifestyle modifications, product avoidance, or alternative therapies. The ability to confirm PEG allergy through a non-invasive blood test significantly improves diagnostic confidence and patient safety.
Patients Scheduled to Receive PEG-Containing Medications
Patients preparing to receive PEG-containing medications—such as laxatives (e.g., PEG 3350), injectable drugs, or PEGylated biologics—represent a key group who can benefit from pre-treatment screening. Detecting PEG-specific IgE in advance helps identify those at increased risk for hypersensitivity reactions and guides clinicians in choosing safer therapeutic alternatives or implementing precautionary measures during administration.
Allergists and Clinicians
Allergists, immunologists, gastroenterologists, dentists, and other healthcare providers involved in administering PEG-containing treatments are central users of our technology. Incorporating PEG IgE testing into routine diagnostic algorithms allows these professionals to detect sensitization early and tailor interventions accordingly. Our platform helps clinicians make evidence-based decisions in both diagnostic and pre-procedural settings, contributing to more personalized and safer patient care.
Biotechnology and Pharmaceutical Companies Involved with PEGylated Products
Companies developing PEGylated drugs or excipient formulations rely on immunogenicity assessments during both preclinical and clinical stages. Anti-PEG IgE screening plays a critical role in risk stratification, patient safety monitoring, and regulatory compliance. Our assay platform supports product development by offering a means to identify anti-PEG antibody responders and de-risk trials through careful subject selection and surveillance.
Vaccine Developers Utilizing PEG-Modified Platforms
Vaccine manufacturers—particularly those using lipid nanoparticle (LNP)-based delivery systems that include PEGylated components—must assess the potential for hypersensitivity responses. Our PEG IgE detection services can be integrated into early-phase trials to identify at-risk populations and inform formulation improvements. Given the global deployment of PEG-modified vaccines, this testing is essential for maximizing public safety and sustaining trust in vaccination programs.